Li Xun, Orr Asuka A, Sajadi Mohammad M, DeVico Anthony L, Deredge Daniel J, MacKerell Alexander D, Hoag Stephen W
School of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland 21201, United States.
Institute of Human Virology, University of Maryland School of Medicine, Baltimore, Maryland 21201, United States.
Mol Pharm. 2025 Apr 7;22(4):1831-1846. doi: 10.1021/acs.molpharmaceut.4c00973. Epub 2025 Mar 3.
N49P9.6-FR-LS and PGT121 are promising antibodies with significant therapeutic potential against HIV infection, but they are prone to precipitation at concentrations greater than 12 to 13 mg/mL. This study evaluates the influence of six excipients─arginine, alanine, sucrose, trehalose, methionine, and glutamate─on the biophysical stability of antibodies. We employed a comprehensive approach, combining computational mAb-excipient interaction analysis via the site-identification by ligand competitive saturation (SILCS) method with extensive experimental characterization. Our experimental matrix included viscosity measurements across temperature gradients, particle size distribution, zeta potential, pH value, and solution appearance, alongside a short-term stability product study at 30 °C and 65% relative humidity, with assessments at t (initial), t (14 days), and t (28 days). Results indicated that sucrose, arginine, alanine, and trehalose provided varying degrees of stabilization for both antibodies. Conversely, glutamate destabilized PGT121 but stabilized N49P9.6-FR-LS, while methionine had a negative effect on N49P9.6-FR-LS but a positive one on PGT121. SILCS-Biologics analysis suggested that stabilization by these excipients is linked to their ability to occupy regions involved in self-protein interactions. Debye-Hückel-Henry charge calculations further indicated that neutral excipients like sucrose and trehalose could alter mAb charges by affecting buffer binding, influencing aggregation propensity. These findings offer valuable insights for optimizing antibody formulations, ensuring enhanced product stability and therapeutic efficacy for HIV treatment.
N49P9.6-FR-LS和PGT121是有前景的抗体,具有抗HIV感染的显著治疗潜力,但它们在浓度大于12至13 mg/mL时容易沉淀。本研究评估了六种辅料(精氨酸、丙氨酸、蔗糖、海藻糖、蛋氨酸和谷氨酸)对抗体生物物理稳定性的影响。我们采用了一种综合方法,将通过配体竞争饱和位点识别(SILCS)方法进行的计算单克隆抗体-辅料相互作用分析与广泛的实验表征相结合。我们的实验矩阵包括跨温度梯度的粘度测量、粒度分布、zeta电位、pH值和溶液外观,以及在30°C和65%相对湿度下的短期稳定性产品研究,并在t(初始)、t(14天)和t(28天)进行评估。结果表明,蔗糖、精氨酸、丙氨酸和海藻糖对两种抗体都提供了不同程度的稳定性。相反,谷氨酸使PGT121不稳定,但使N49P9.6-FR-LS稳定,而蛋氨酸对N49P9.6-FR-LS有负面影响,但对PGT121有正面影响。SILCS-生物制剂分析表明,这些辅料的稳定作用与其占据参与自身蛋白质相互作用区域的能力有关。德拜-休克尔-亨利电荷计算进一步表明,蔗糖和海藻糖等中性辅料可通过影响缓冲液结合来改变单克隆抗体的电荷,从而影响聚集倾向。这些发现为优化抗体制剂提供了有价值的见解,确保提高HIV治疗产品的稳定性和治疗效果。